Literature DB >> 16837691

EGFR mutations in small-cell lung cancers in patients who have never smoked.

Maureen F Zakowski, Marc Ladanyi, Mark G Kris.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16837691     DOI： 10.1056/NEJMc053610

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  111 in total

1.  Lung cancers with acquired resistance to EGFR inhibitors occasionally harbor BRAF gene mutations but lack mutations in KRAS, NRAS, or MEK1.

Authors:  Kadoaki Ohashi; Lecia V Sequist; Maria E Arcila; Teresa Moran; Juliann Chmielecki; Ya-Lun Lin; Yumei Pan; Lu Wang; Elisa de Stanchina; Kazuhiko Shien; Keisuke Aoe; Shinichi Toyooka; Katsuyuki Kiura; Lynnette Fernandez-Cuesta; Panos Fidias; James Chih-Hsin Yang; Vincent A Miller; Gregory J Riely; Mark G Kris; Jeffrey A Engelman; Cindy L Vnencak-Jones; Dora Dias-Santagata; Marc Ladanyi; William Pao
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-06       Impact factor: 11.205

2.  Molecular and Histological Changes in Post-Treatment Biopsies of Non-Squamous Non-Small Cell Lung Cancer: A Retrospective Study.

Authors:  S Vatrano; L Righi; T Vavalá; I Rapa; M Busso; S Izzo; S Cappia; A Veltri; M Papotti; G V Scagliotti; S Novello
Journal:  Target Oncol       Date:  2016-04       Impact factor: 4.493

3.  A novel PI3K inhibitor iMDK suppresses non-small cell lung Cancer cooperatively with A MEK inhibitor.

Authors:  Naomasa Ishida; Takuya Fukazawa; Yutaka Maeda; Tomoki Yamatsuji; Katsuya Kato; Kenichi Matsumoto; Tsuyoshi Shimo; Nagio Takigawa; Jeffrey A Whitsett; Yoshio Naomoto
Journal:  Exp Cell Res       Date:  2015-04-01       Impact factor: 3.905

4.  Concurrent RB1 and TP53 Alterations Define a Subset of EGFR-Mutant Lung Cancers at risk for Histologic Transformation and Inferior Clinical Outcomes.

Authors:  Michael Offin; Joseph M Chan; Megan Tenet; Hira A Rizvi; Ronglai Shen; Gregory J Riely; Natasha Rekhtman; Yahya Daneshbod; Alvaro Quintanal-Villalonga; Alexander Penson; Matthew D Hellmann; Maria E Arcila; Marc Ladanyi; Dana Pe'er; Mark G Kris; Charles M Rudin; Helena A Yu
Journal:  J Thorac Oncol       Date:  2019-06-19       Impact factor: 15.609

Review 5.  Drug Resistance to EGFR Inhibitors in Lung Cancer.

Authors:  Osamu Tetsu; Matthew J Hangauer; Janyaporn Phuchareon; David W Eisele; Frank McCormick
Journal:  Chemotherapy       Date:  2016-02-25       Impact factor: 2.544

Review 6.  The quest to overcome resistance to EGFR-targeted therapies in cancer.

Authors:  Curtis R Chong; Pasi A Jänne
Journal:  Nat Med       Date:  2013-11-07       Impact factor: 53.440

Review 7.  Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin.

Authors:  Matthew G Oser; Matthew J Niederst; Lecia V Sequist; Jeffrey A Engelman
Journal:  Lancet Oncol       Date:  2015-04       Impact factor: 41.316

Review 8.  Management of acquired resistance to epidermal growth factor receptor kinase inhibitors in patients with advanced non-small cell lung cancer.

Authors:  Adrian G Sacher; Pasi A Jänne; Geoffrey R Oxnard
Journal:  Cancer       Date:  2014-04-17       Impact factor: 6.860

Review 9.  Combating acquired resistance to tyrosine kinase inhibitors in lung cancer.

Authors:  Christine M Lovly
Journal:  Am Soc Clin Oncol Educ Book       Date:  2015

10.  Targeted therapies in small cell lung cancer.

Authors:  Hong-Yang Lu; Xiao-Jia Wang; Wei-Min Mao
Journal:  Oncol Lett       Date:  2012-07-06       Impact factor: 2.967
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.